Nomura Maintains Neutral Rating on Torrent Pharma, Sets Rs 4,670 Target
Nomura expects strong Q2 FY27 results, market-beating growth in India, export tailwinds from rupee depreciation and early synergies from the JB Pharma acquisition.
Nomura expects Torrent Pharmaceuticals to report strong second-quarter results for FY27, with market-beating growth in India, tailwinds from rupee depreciation for its export business and early realisation of cost synergies from the JB Pharma acquisition.In a quick note dated October 21, Nomura sai…